Abstract
Purpose: We evaluated the efficacy of synchronous three-dimensional (3D) conformal boost to the gross tumor volume (GTV) in concurrent chemoradiotherapy for patients with locally advanced non-small-cell lung cancer (NSCLC). Methods and Materials: Eligibility included unresectable Stage III NSCLC with no pleural effusion, no supraclavicular nodal metastases, and Eastern Cooperative Oncology Group performance score of 0-1. Forty-nine patients with pathologically proven NSCLC were enrolled. Eighteen patients had Stage IIIA and 31 had Stage IIIB. By using 3D conformal radiotherapy (RT) techniques, a dose of 1.8 Gy was delivered to the planning target volume with a synchronous boost of 0.6 Gy to the GTV, with a total dose of 60 Gy to the GTV and 45 Gy to the planning target volume in 25 fractions during 5 weeks. All patients received weekly chemotherapy consisting of paclitaxel and carboplatin during RT. Results: With a median follow-up of 36.8 months (range, 29.0-45.5 months) for surviving patients, median survival was 28.1 months. One-, 2- and 3-year overall survival rates were 77%, 56.4%, and 43.8%, respectively. Corresponding local progression-free survival rates were 71.2%, 53.7%, and 53.7%. Compliance was 90% for RT and 88% for chemotherapy. Acute esophagitis of Grade 2 or higher occurred in 29 patients.
More>>
Cho, Kwan Ho , E-mail: kwancho@ncc.re.kr;
[1]
Ahn, Sung Ja;
[2]
Pyo, Hong Ryull;
[1]
Kim, Kyu-Sik;
Kim, Young-Chul;
[2]
Moon, Sung Ho;
Han, Ji-Youn;
Kim, Heung Tae;
[1]
Koom, Woong Sub;
[3]
Lee, Jin Soo
[1]
- Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi (Korea, Republic of)
- Chonnam National University Hwasun Hospital, Hwasun, Chonnam (Korea, Republic of)
- Yonsei University Medical Center, Seoul (Korea, Republic of)
Citation Formats
Cho, Kwan Ho , E-mail: kwancho@ncc.re.kr, Ahn, Sung Ja, Pyo, Hong Ryull, Kim, Kyu-Sik, Kim, Young-Chul, Moon, Sung Ho, Han, Ji-Youn, Kim, Heung Tae, Koom, Woong Sub, and Lee, Jin Soo.
A Phase II Study of Synchronous Three-Dimensional Conformal Boost to the Gross Tumor Volume for Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: Results of Korean Radiation Oncology Group 0301 Study.
United States: N. p.,
2009.
Web.
doi:10.1016/j.ijrobp.2008.10.020.
Cho, Kwan Ho , E-mail: kwancho@ncc.re.kr, Ahn, Sung Ja, Pyo, Hong Ryull, Kim, Kyu-Sik, Kim, Young-Chul, Moon, Sung Ho, Han, Ji-Youn, Kim, Heung Tae, Koom, Woong Sub, & Lee, Jin Soo.
A Phase II Study of Synchronous Three-Dimensional Conformal Boost to the Gross Tumor Volume for Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: Results of Korean Radiation Oncology Group 0301 Study.
United States.
https://doi.org/10.1016/j.ijrobp.2008.10.020
Cho, Kwan Ho , E-mail: kwancho@ncc.re.kr, Ahn, Sung Ja, Pyo, Hong Ryull, Kim, Kyu-Sik, Kim, Young-Chul, Moon, Sung Ho, Han, Ji-Youn, Kim, Heung Tae, Koom, Woong Sub, and Lee, Jin Soo.
2009.
"A Phase II Study of Synchronous Three-Dimensional Conformal Boost to the Gross Tumor Volume for Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: Results of Korean Radiation Oncology Group 0301 Study."
United States.
https://doi.org/10.1016/j.ijrobp.2008.10.020.
@misc{etde_21276936,
title = {A Phase II Study of Synchronous Three-Dimensional Conformal Boost to the Gross Tumor Volume for Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: Results of Korean Radiation Oncology Group 0301 Study}
author = {Cho, Kwan Ho , E-mail: kwancho@ncc.re.kr, Ahn, Sung Ja, Pyo, Hong Ryull, Kim, Kyu-Sik, Kim, Young-Chul, Moon, Sung Ho, Han, Ji-Youn, Kim, Heung Tae, Koom, Woong Sub, and Lee, Jin Soo}
abstractNote = {Purpose: We evaluated the efficacy of synchronous three-dimensional (3D) conformal boost to the gross tumor volume (GTV) in concurrent chemoradiotherapy for patients with locally advanced non-small-cell lung cancer (NSCLC). Methods and Materials: Eligibility included unresectable Stage III NSCLC with no pleural effusion, no supraclavicular nodal metastases, and Eastern Cooperative Oncology Group performance score of 0-1. Forty-nine patients with pathologically proven NSCLC were enrolled. Eighteen patients had Stage IIIA and 31 had Stage IIIB. By using 3D conformal radiotherapy (RT) techniques, a dose of 1.8 Gy was delivered to the planning target volume with a synchronous boost of 0.6 Gy to the GTV, with a total dose of 60 Gy to the GTV and 45 Gy to the planning target volume in 25 fractions during 5 weeks. All patients received weekly chemotherapy consisting of paclitaxel and carboplatin during RT. Results: With a median follow-up of 36.8 months (range, 29.0-45.5 months) for surviving patients, median survival was 28.1 months. One-, 2- and 3-year overall survival rates were 77%, 56.4%, and 43.8%, respectively. Corresponding local progression-free survival rates were 71.2%, 53.7%, and 53.7%. Compliance was 90% for RT and 88% for chemotherapy. Acute esophagitis of Grade 2 or higher occurred in 29 patients. Two patients with T4 lesions died of massive bleeding and hemoptysis during treatment (Grade 5). Overall late toxicity was acceptable. Conclusions: Based on the favorable outcome with acceptable toxicity, the acceleration scheme using 3D conformal GTV boost in this trial is warranted to compare with conventional fractionation in a Phase III trial.}
doi = {10.1016/j.ijrobp.2008.10.020}
journal = []
issue = {5}
volume = {74}
place = {United States}
year = {2009}
month = {Aug}
}
title = {A Phase II Study of Synchronous Three-Dimensional Conformal Boost to the Gross Tumor Volume for Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: Results of Korean Radiation Oncology Group 0301 Study}
author = {Cho, Kwan Ho , E-mail: kwancho@ncc.re.kr, Ahn, Sung Ja, Pyo, Hong Ryull, Kim, Kyu-Sik, Kim, Young-Chul, Moon, Sung Ho, Han, Ji-Youn, Kim, Heung Tae, Koom, Woong Sub, and Lee, Jin Soo}
abstractNote = {Purpose: We evaluated the efficacy of synchronous three-dimensional (3D) conformal boost to the gross tumor volume (GTV) in concurrent chemoradiotherapy for patients with locally advanced non-small-cell lung cancer (NSCLC). Methods and Materials: Eligibility included unresectable Stage III NSCLC with no pleural effusion, no supraclavicular nodal metastases, and Eastern Cooperative Oncology Group performance score of 0-1. Forty-nine patients with pathologically proven NSCLC were enrolled. Eighteen patients had Stage IIIA and 31 had Stage IIIB. By using 3D conformal radiotherapy (RT) techniques, a dose of 1.8 Gy was delivered to the planning target volume with a synchronous boost of 0.6 Gy to the GTV, with a total dose of 60 Gy to the GTV and 45 Gy to the planning target volume in 25 fractions during 5 weeks. All patients received weekly chemotherapy consisting of paclitaxel and carboplatin during RT. Results: With a median follow-up of 36.8 months (range, 29.0-45.5 months) for surviving patients, median survival was 28.1 months. One-, 2- and 3-year overall survival rates were 77%, 56.4%, and 43.8%, respectively. Corresponding local progression-free survival rates were 71.2%, 53.7%, and 53.7%. Compliance was 90% for RT and 88% for chemotherapy. Acute esophagitis of Grade 2 or higher occurred in 29 patients. Two patients with T4 lesions died of massive bleeding and hemoptysis during treatment (Grade 5). Overall late toxicity was acceptable. Conclusions: Based on the favorable outcome with acceptable toxicity, the acceleration scheme using 3D conformal GTV boost in this trial is warranted to compare with conventional fractionation in a Phase III trial.}
doi = {10.1016/j.ijrobp.2008.10.020}
journal = []
issue = {5}
volume = {74}
place = {United States}
year = {2009}
month = {Aug}
}